What is the appropriate management of emphysema identified on chest X‑ray in a never‑smoker?

Management of Emphysema in Never-Smokers

Test immediately for alpha-1 antitrypsin (A1AT) deficiency in any never-smoker presenting with emphysematous changes on chest x-ray, as this is the most likely underlying cause and requires specific targeted therapy. 1, 2

Immediate Diagnostic Workup

The finding of emphysema in a never-smoker is highly abnormal and demands investigation for secondary causes:

Priority Testing for A1AT Deficiency

• Measure serum A1AT level (functional level <11 mmol/L or <0.57 g/L indicates severe deficiency) 1
• Obtain SERPINA1 genotyping if levels are low to identify specific variants (PIZZ, PISZ, PI*MZ) 1, 2
• This testing is critical because A1AT deficiency is the most common genetic cause of emphysema in never-smokers and has specific treatment implications 2

Confirm and Quantify Emphysema

• Obtain high-resolution CT chest with both thin slices (morphology) and thick slices (densitometry) - this is far superior to chest x-ray for detecting and quantifying emphysema 2
• CT densitometry using the "density mask" method (highlighting pixels <-910 HU) provides quantitative assessment of emphysema extent 2
• Perform complete pulmonary function testing including spirometry, lung volumes, and diffusion capacity (DLCO) 2

Consider Other Secondary Causes

Beyond A1AT deficiency, evaluate for:

• Connective tissue diseases (particularly systemic sclerosis/scleroderma) - can cause combined pulmonary fibrosis and emphysema even in never-smokers 3
• Congenital lobar emphysema - rare but can present in young adults 4
• Occupational/environmental exposures - gas, fumes, dust, passive smoke, kerosene heaters 2

Treatment Algorithm Based on A1AT Status

If A1AT Deficiency is Confirmed (PIZZ or PISZ)

Strongly recommend A1AT augmentation therapy if ALL of the following criteria are met: 1

1. Never-smoker or former smoker (must have quit)
2. FEV₁ <80% predicted
3. Documented emphysema on CT
4. Severely reduced A1AT level (<11 mmol/L or <0.57 g/L)
5. Confirmed SERPINA1 genotype associated with deficiency
6. Already receiving optimal COPD therapy

The 2025 Canadian Thoracic Society guideline provides high-quality evidence that augmentation therapy preserves CT lung density and very low-quality evidence for reduced mortality 1. The evidence is strongest for patients with moderate airflow obstruction (FEV₁ 35-60% predicted) 2.

Critical caveat: Augmentation therapy is NOT recommended for individuals without established emphysema, even with documented A1AT deficiency 2.

Standard COPD Management (Regardless of A1AT Status)

All never-smokers with emphysema require comprehensive COPD management 2:

• Inhaled bronchodilators: Long-acting beta-2 agonists (LABA) and/or long-acting muscarinic antagonists (LAMA) - use even if objective bronchodilator response is lacking, as many find symptomatic benefit 2
• Inhaled corticosteroids: Only if documented bronchial hyperreactivity or positive response to oral corticosteroid trial 2
• Vaccinations: Annual influenza and pneumococcal vaccines 2
• Supplemental oxygen: When indicated by standard criteria (PaO₂ <55 mmHg or SpO₂ <88%) 2
• Pulmonary rehabilitation: For any functional impairment 2
• Early antibiotic therapy: For ALL purulent exacerbations (infection increases elastolytic burden in A1AT deficiency) 2

Environmental and Preventive Measures

Absolute avoidance of:

• All forms of smoking (including vaping, cannabis) 1
• Passive/secondhand smoke exposure 2
• Occupational irritants (dust, fumes, gases) - may require job change 2

Hepatitis screening and vaccination: Test for hepatitis B and C serology; vaccinate against hepatitis B if liver disease is present (A1AT deficiency carries liver disease risk) 2

Monitoring and Prognosis

• FEV₁ is the strongest predictor of survival - 2-year survival remains normal until FEV₁ drops below 35% predicted 2
• Repeat spirometry every 3-6 months (more frequent testing adds little value) 2
• CT densitometry may be more sensitive than FEV₁ for tracking emphysema progression 2
• Never-smokers with A1AT deficiency who avoid all smoking have near-normal life expectancy if diagnosed early 2

Key Clinical Pitfalls

1. Don't dismiss emphysema findings in never-smokers - this is pathological and requires investigation
2. Don't delay A1AT testing - early diagnosis allows intervention before severe lung damage occurs
3. Don't start augmentation therapy without confirming ALL eligibility criteria - it's not indicated for preserved lung function
4. Don't forget to assess for passive smoke and occupational exposures - these accelerate disease even in genetic forms 2